Related Experiment Videos
How to inhibit telomerase activity for cancer therapy
1Department of Obstetrics and Gynecology, Kanazawa University, School of Medicine, 13-1, Takaramachi, Kanazawa, Ishikawa 920-8641, Japan. satoruky@med.kanazawa-u.ac.jp
Abstract:
Telomerase is a target for anticancer research because telomerase activity is closely correlated with malignancy. Inhibition of telomerase activity should increase telomere shortening, which destabilizes chromosomes, thus leading to cellular senescence and death. Extensive investigations have addressed the molecular mechanisms of telomerase activation in cancers. Based on results from these studies, various attempts have been made to inhibit telomerase activity using molecular techniques in cancer cells. Antisense oligonucleotides directed to human telomerase RNA, the dominant negative form of human telomerase reverse transcriptase (hTERT), hammerhead ribozymes that cut hTR and agents that interact with quadruplex DNA represent potential telomerase inhibitors. This review includes a summary of recent attempts to inhibit telomerase activity in cancer cells and a discussion of how these tools can be applied to cancer therapy, especially in combination with established anti-cancer agents.
Insights
Telomerase inhibitors offer a promising anticancer strategy by promoting telomere shortening and cell death. This review explores molecular techniques to inhibit telomerase activity for cancer therapy.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Telomerase activity is strongly linked to cancer development and progression.
- Understanding telomerase activation mechanisms is crucial for developing targeted cancer therapies.
- Telomere shortening leads to chromosomal instability, cellular senescence, and apoptosis.
Purpose of the Study:
- To review recent advancements in inhibiting telomerase activity in cancer cells.
- To discuss the therapeutic potential of telomerase inhibitors in cancer treatment.
- To explore the combination of telomerase inhibitors with existing anti-cancer agents.
Main Methods:
- Antisense oligonucleotides targeting human telomerase RNA (hTR).
- Dominant-negative human telomerase reverse transcriptase (hTERT) constructs.
- Hammerhead ribozymes for hTR cleavage.
- Small molecules interacting with telomeric G-quadruplex DNA.
Main Results:
- Various molecular strategies effectively inhibit telomerase activity in cancer cells.
- These inhibitors induce telomere shortening and subsequent cell death.
- Preclinical studies demonstrate the potential of these agents in cancer models.
Conclusions:
- Telomerase inhibition represents a viable strategy for cancer therapy.
- Combination therapies involving telomerase inhibitors and conventional agents may enhance treatment efficacy.
- Further research is warranted to translate these findings into clinical applications.